TY - JOUR
T1 - The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice
AU - The, Frans O.
AU - de Jonge, Wouter J.
AU - Bennink, Roel J.
AU - van den Wijngaard, Rene M.
AU - Boeckxstaens, Guy E.
PY - 2005
Y1 - 2005
N2 - 1 Intestinal manipulation (IM) during abdominal surgery triggers the influx of inflammatory cells, leading to postoperative ileus. Prevention of this local muscle inflammation, using intercellular adhesion molecule-1 ( ICAM-1) and leukocyte function-associated antigen-1-specific antibodies, has been shown to shorten postoperative ileus. However, the therapeutic use of antibodies has considerable disadvantages. 2 The aim of the current study was to evaluate the effect of ISIS-3082, a mouse-specific ICAM-1 antisense oligonucleotide, on postoperative ileus in mice. 3 Mice underwent a laparotomy or a laparotomy combined with IM after treatment with ICAM-1 antibodies, 0.1-10 mg kg(-1) ISIS-3082, saline or ISIS-8997 ( scrambled control antisense oligonucleotides, 1 and 3 mg kg(-1)). At 24 h after surgery, gastric emptying of a (TC)-T-99m labelled semi-liquid meal was determined using scintigraphy. Intestinal inflammation was assessed by myeloperoxidase ( MPO) activity in ileal muscle whole mounts. 4 IM significantly reduced gastric emptying compared to laparotomy. Pretreatment with ISIS-3082 ( 0.1-1 mg kg(-1)) as well as ICAM-1 antibodies ( 10 mg kg(-1)), but not ISIS-8997 or saline, improved gastric emptying in a dose-dependent manner. This effect diminished with higher doses of ISIS-3082 ( 3-10 mg kg(-1)). 5 Similarly, ISIS-3082 ( 0.1-1 mg kg(-1)) and ICAM-1 antibodies, but not ISIS-8997 or higher doses of ISIS-3082 ( 3-10mg kg(-1)), reduced manipulation-induced inflammation. Immunohistochemistry showed reduction of ICAM-1 expression with ISIS-3082 only. 6 ISIS-3082 pretreatment prevents postoperative ileus in mice by reduction of manipulation-induced local intestinal muscle inflammation. Our data suggest that targeting ICAM-1 using antisense oligonucleotides may represent a new therapeutic approach to the prevention of postoperative ileus
AB - 1 Intestinal manipulation (IM) during abdominal surgery triggers the influx of inflammatory cells, leading to postoperative ileus. Prevention of this local muscle inflammation, using intercellular adhesion molecule-1 ( ICAM-1) and leukocyte function-associated antigen-1-specific antibodies, has been shown to shorten postoperative ileus. However, the therapeutic use of antibodies has considerable disadvantages. 2 The aim of the current study was to evaluate the effect of ISIS-3082, a mouse-specific ICAM-1 antisense oligonucleotide, on postoperative ileus in mice. 3 Mice underwent a laparotomy or a laparotomy combined with IM after treatment with ICAM-1 antibodies, 0.1-10 mg kg(-1) ISIS-3082, saline or ISIS-8997 ( scrambled control antisense oligonucleotides, 1 and 3 mg kg(-1)). At 24 h after surgery, gastric emptying of a (TC)-T-99m labelled semi-liquid meal was determined using scintigraphy. Intestinal inflammation was assessed by myeloperoxidase ( MPO) activity in ileal muscle whole mounts. 4 IM significantly reduced gastric emptying compared to laparotomy. Pretreatment with ISIS-3082 ( 0.1-1 mg kg(-1)) as well as ICAM-1 antibodies ( 10 mg kg(-1)), but not ISIS-8997 or saline, improved gastric emptying in a dose-dependent manner. This effect diminished with higher doses of ISIS-3082 ( 3-10 mg kg(-1)). 5 Similarly, ISIS-3082 ( 0.1-1 mg kg(-1)) and ICAM-1 antibodies, but not ISIS-8997 or higher doses of ISIS-3082 ( 3-10mg kg(-1)), reduced manipulation-induced inflammation. Immunohistochemistry showed reduction of ICAM-1 expression with ISIS-3082 only. 6 ISIS-3082 pretreatment prevents postoperative ileus in mice by reduction of manipulation-induced local intestinal muscle inflammation. Our data suggest that targeting ICAM-1 using antisense oligonucleotides may represent a new therapeutic approach to the prevention of postoperative ileus
U2 - https://doi.org/10.1038/sj.bjp.0706303
DO - https://doi.org/10.1038/sj.bjp.0706303
M3 - Article
C2 - 15997238
SN - 0007-1188
VL - 146
SP - 252
EP - 258
JO - British journal of pharmacology
JF - British journal of pharmacology
IS - 2
ER -